It's used to treat chest infections such as pneumonia, skin problems such as cellulitis, and ear infections
The results showed that UGT1A1, UGT1A4, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 were included in TRRUST
5–9
A high level of miR-200a/-183 indicates a low level of UGT1A9, thus reducing the formation of sorafenib β-D-glucuronic acid in HCC and reducing the efficacy of drugs
500 mg bid 7 days; 3
It works by stopping the growth of bacteria
Ugt1a9 Proteins Recombinant Mouse UDP-glucuronosyltransferase 1-9 (Ugt1a9), partial ( Yeast-CSB-YP733827MO1 E
Oct 24, 2016 · Human UGT1A9 is uniquely stable against a heat treatment as well (Fujiwara et al
It works by stopping the growth of bacteria
Enzyme kinetic fits were performed by non-linear regression analysis using SigmaPlot software (version 11)
clarithromycin will increase the level or effect of nicardipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism
399C>T, rs2011404, rs6759892, rs7577677, rs4148323, UGT1A9*2 and UGT1A9*3) from a Phase 2 study conducted in subjects with T2DM (n =
Renal cells express high amounts of UGT; however, the significance of UGT in patients with renal cell carcinoma (RCC) remains unknown
The drug exerts its action by binding to 23s rRNA (with nucleotides in domains II and V)
Feb 23, 2022 · The presence of UGT1A9 polymorphisms was significantly higher in the patient group that did not respond to MPA treatment compared to the group that did respond to MPA treatment (Table 1)
Expression levels and the activity of UGT1A9 may depend on the presence of some SNPs located in the gene promoter region (-2152C>T and -275T>A), as well as changes in the coding region
red, irritated eyes
The structural modifications made to erythromycin significantly changed the spectrum of Here, we aimed to characterize diurnal rhythm of Ugt1a9 in mouse liver and to determine the molecular mechanisms underlying the rhythmicity
Aug 14, 2007 · Genetic polymorphisms in hepatically expressed UGT1A1 and UGT1A9 contribute to the interindividual variability i-n irinotecan disposition and toxicity
Nov 1, 2020 · 目的 在一项使用甲芬那酸作为 UGT1A9 抑制剂的临床 DDI 研究中,未观察到健康受试者中 vericiguat 暴露的临床相关增加(EudraCT 2014-000764-17)。 该分析旨在通过全动态生理药代动力学 (PBPK) 建模,前瞻性地研究阿扎那韦作为选择性 UGT1A1 抑制剂的 DDI 潜力作为外在因素。 Jun 1, 2021 · A total of 16 natural products (P1-P16), most of which are flavonoids, were screened for their potential as UGT1A9 probe substrates by incubating with HLMs